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It was estimated that over 36 million people were living with HIV globally in 2016 with only 19.5
million receiving access to antiretroviral therapy (ART)1. Maraviroc (MVC) is an orally dosed entry
inhibitor which targets the CCR5 co-receptor to prevent entry of CCR5-trophic virus into T-cells2. Oral
dosing presents a simple route of self-administration but is often limited by low bioavailability. MVC
is a substrate for P-glycoprotein (P-gp), limiting permeability. Additionally, it is estimated that over
60% of the absorbed drug is metabolised by CYP3A4, resulting in a bioavailability of ~33%3. Current
MVC-containing ART regimens require twice-daily administration to maintain MVC plasma
concentrations within the therapeutic range. Preferred ART regimens involve once daily dosing, but
the MVC dose cannot be increased due to potential risk of postural hypotension, reported at Cmax
4.
The aims of this study were to develop MVC Solid Drug Nanoparticles (SDNs) using an emulsion-
templated freeze-drying technique (ETFD)5, with a higher bioavailability and a lower Cmax:Cmin ratio
in rodent, potentially enabling a once-daily fixed dose combination product (FDC).
MVC 
Nanodispersion
MVC loading 
(wt.%)
Z-average 
size (nm)
PDI
1 70% 728 0.345
2* 70% 171 0.170
Table 1. MVC SDNs characterised using dynamic light 
scattering (Malvern Instruments, UK)
SDN Production and Characterisation
An ETFD screen was used to produce and
optimise solid drug nanosuspensions of MVC,
achieving up to 70 wt.% drug-loading. The lead
formulations which showed enhanced
permeability and progressed to In vivo studies
are outlined in Table 1.
In vitro Apparent Permeability
The results in Figure 1. indicate that formulation of
MVC into SDNs increased the apparent oral
absorption of the drug across Caco-2 monolayers.
Specifically:
• Nanodispersion 1 increased the MVC Papp ratio over
1.7-fold compared to the conventional
unformulated MVC.
• The soybean oil blended formulation,
nanodispersion 2, increased the MVC Papp ratio
over 4.3-fold.
*Soybean oil blended formulation 
Figure 1. The Papp ratio of conventional and
SDN formulated MVC. Monolayers were
incubated for 1 h at 37oC, 5% CO2.
*, P<0.05 (Two-tailed unpaired t-test)
(±SD, n=4).
In vivo Oral Pharmacokinetics
Enhanced MVC exposure was highlighted following the
oral dosing of nanodispersions 1 (Fig. 2 A) and 2 (Fig. 2
B) compared to an equivalent conventional MVC dose in
male Wistar rats.
The pharmacokinetic parameters in Table 2. highlight:
• A 2.4- and 2.5-fold increase in AUC0-4 and Cave,
respectively, and a 1.65-fold reduction in the Cmax:Cmin
ratio for nanodispersion 1 compared to the
conventional MVC preparation.
• A 2.4-, 2.8- and 4.5-fold increase in AUC0-4, Cave and
Cmax:Cmin ratio, respectively, for the oil blended
formulation, nanodispersion 2, compared to the
conventional MVC preparation.
Pharmacokinetic 
parameter
Conventional
MVC
Nanodispersion 
1
Nanodispersion 
2
Cmax (ng ml
-1) 26.52 50.74 130.31
Cmin (ng ml
-1) 8.16 25.83 8.88
AUC0-4 (ng.h ml
-1) 58.71 145.33 146.24
Cavg (ng ml
-1) 15.17 38.38 43.06
Tmax (h) 1.5 1.5 1.0
Cmax:Cmin ratio 3.25 1.96 14.67
Figure 2. MVC plasma
concentration in adult male
Wistar rats dosed with either
nanodispersion 1 (A.), 2 (B.) or a
conventional MVC dose (10 mg
Kg-1 MVC) via oral gavage. (±SD,
n=4). All In vivo work was
conducted in accordance with the
Animals (Scientific Procedures)
Act 1986 (ASPA) implemented by
the UK Home Office.
Table 2. Pharmacokinetic parameters of MVC following oral dosing.
Parameters were calculated from the exposure curves outlined in Fig 2.
Tissue Distribution
Increased MVC concentrations were observed in most tissues
obtained from the nanodispersion dosed rats (Fig. 3).
Specifically;
• A 2.2- (P=<0.001), 1.6- (P=<0.001) and 1.8-fold (P=0.0057)
increase was observed in the liver, spleen and kidney,
respectively, in the rats dosed with nanodispersion 1.
• A 3.8- (P=0.001), 2.4- (P=0.0227), 1.9- (P=0.0014), 4.6-
(P=0.0040) and 1.6-fold (P=0.0173) increase was observed in
the liver, spleen, kidney, lung and heart, respectively, in the
rats dosed with nanodispersion 2.
Figure 3. MVC tissue concentrations.
*, P<0.05; **, P<0.01; ***, P<0.001
(Unpaired two-tailed t-test)
(±SD, n=4).
The nanomedicines presented here have the potential to enable once-daily dosing of MVC, reducing
the dose required for viral suppression and may enable the development of novel ART FDCs.
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